Genentech, part of the Roche Group (SIX:RO (SIX:ROG) (OTCQX:RHHBY), revealed on Thursday that the US Food and Drug Administration (FDA) has approved a Tecentriq (atezolizumab) combination therapy for people with advanced melanoma.
Tecentriq plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) was approved for the treatment of BRAF V600 mutation-positive advanced melanoma patients.
The approval was based on results from the Phase III IMspire150 study, which showed that the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without their disease worsening or death (progression-free survival), compared to placebo plus Cotellic and Zelboraf.
The supplemental Biologics License Application (sBLA) for Tecentriq was granted under Priority Review.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering